CINECA IRIS Institutional Research Information System

FESTUCCIA, MORENO BENEDETTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.582
EU - Europa 3.271
AS - Asia 1.778
SA - Sud America 189
AF - Africa 67
OC - Oceania 60
Continente sconosciuto - Info sul continente non disponibili 15
Totale 9.962
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.441
CN - Cina 867
IT - Italia 780
DE - Germania 647
FR - Francia 294
SE - Svezia 239
JP - Giappone 218
IE - Irlanda 206
SG - Singapore 200
GB - Regno Unito 169
ES - Italia 167
AT - Austria 165
FI - Finlandia 132
CA - Canada 105
TR - Turchia 96
KR - Corea 91
PL - Polonia 88
VN - Vietnam 74
UA - Ucraina 64
BR - Brasile 63
IN - India 55
NL - Olanda 54
AU - Australia 50
SN - Senegal 46
AR - Argentina 43
BE - Belgio 41
CO - Colombia 41
TW - Taiwan 36
RU - Federazione Russa 35
GR - Grecia 34
ID - Indonesia 29
MX - Messico 28
HK - Hong Kong 27
DK - Danimarca 26
PE - Perù 25
HU - Ungheria 24
CH - Svizzera 22
TH - Thailandia 22
BY - Bielorussia 21
IL - Israele 20
PT - Portogallo 18
CL - Cile 15
JO - Giordania 11
RO - Romania 11
NZ - Nuova Zelanda 10
SI - Slovenia 10
CZ - Repubblica Ceca 8
EU - Europa 8
UZ - Uzbekistan 8
ZA - Sudafrica 8
AP - ???statistics.table.value.countryCode.AP??? 7
IR - Iran 7
SA - Arabia Saudita 7
HR - Croazia 6
AZ - Azerbaigian 5
EG - Egitto 5
PA - Panama 3
RS - Serbia 3
TN - Tunisia 3
CR - Costa Rica 2
CU - Cuba 2
EC - Ecuador 2
KE - Kenya 2
MA - Marocco 2
PH - Filippine 2
PK - Pakistan 2
BG - Bulgaria 1
EE - Estonia 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MY - Malesia 1
NO - Norvegia 1
PR - Porto Rico 1
SK - Slovacchia (Repubblica Slovacca) 1
TZ - Tanzania 1
Totale 9.962
Salva come PNG Salva come JPEG
Città #
Beijing 364
Fairfield 330
Chandler 291
Santa Clara 226
Houston 219
Dublin 198
Wilmington 194
Ashburn 191
Singapore 172
Torino 165
Woodbridge 159
Seattle 155
Redwood City 142
Vienna 141
Ann Arbor 137
Cambridge 124
Pisa 113
Dearborn 110
Villeurbanne 103
Nyköping 93
Tokyo 82
New York 76
Shanghai 76
Warsaw 71
Medford 64
Princeton 62
Columbus 60
Dong Ket 55
Jacksonville 51
Madrid 50
Florence 46
Munich 44
Milan 40
Guangzhou 36
Paris 33
Rome 32
Helsinki 27
Jakarta 27
Ankara 26
Toronto 26
Fremont 25
London 25
Nanjing 25
Buenos Aires 23
Hangzhou 23
Taipei 23
Duncan 22
Düsseldorf 22
San Mateo 22
Wuhan 22
Boston 21
Rochester 21
Chicago 20
Istanbul 20
Phoenix 20
San Diego 20
Turin 20
Zhengzhou 20
Hefei 19
Lima 19
Brussels 17
Nürnberg 17
Bogotá 16
Los Angeles 15
Bologna 14
Budapest 14
Chengdu 14
Nanning 14
Ottawa 14
Athens 13
Boardman 13
Changsha 13
Faenza 13
Osaka 13
Philadelphia 13
Saint Louis 13
Seoul 13
Xian 13
Brescia 12
Salt Lake City 12
Tianjin 12
Denver 11
Leipzig 11
Sydney 11
São Paulo 11
Baltimore 10
Essen 10
Fuzhou 10
Santiago 10
Valencia 10
Barcelona 9
Birmingham 9
Brooklyn 9
Buffalo 9
Cleveland 9
Frankfurt am Main 9
Leawood 9
Minneapolis 9
San Francisco 9
Amman 8
Totale 5.514
Salva come PNG Salva come JPEG
Nome #
Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation 2.754
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. 493
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors 480
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 427
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation 404
Extracellular vesicles as potential biomarkers of acute graft-vs.-host-disease 299
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma 264
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 263
CLINICAL IMPACT OF IMMUNOPHENOTYPIC REMISSION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MULTIPLE MYELOMA 238
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 205
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation. 165
Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability. 156
A POST-REMISSION MAINTENANCE TREATMENT WITH LOW-DOSE CHEMOTHERAPY + RETINOIDS AND DIHYDROXYLATED VITAMIN D3 MAY IMPROVE THE SURVIVAL OF POOR-PROGNOSIS AML/MDS PATIENTS 156
null 148
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the italian bone marrow donor registry. 146
Late-Onset Hepatic Veno-Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide 145
THYMIC FUNCTION AND EARLY T CELL RECONSTITUTION AFTER HAPLOIDENTICAL MARROW TRANSPLANTATION 143
Restoring natural killer cell immunity against multiple myeloma in the era of new drugs 141
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. 141
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 133
Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report 130
Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma 122
Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients 122
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 122
IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA 119
IMMUNOPHENOTYPIC REMISSION AFTER ALLOGRAFTING IN MULTIPLE MYELOMA 115
Is there a role for allografting in myeloma ?: an update of a comparative study 109
Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma 109
Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients 109
IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA 107
TREATMENT OF POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) HAEMORRHAGIC CYSTITIS WITH INTRAVESCICAL HYALURONIC ACID 106
ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA 105
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 97
RECONSTITUTION OF THE T CELL COMPARTMENT AND THE THYMIC FUNCTION AFTER REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 96
ROLE OF ALLOGRAFTING IN ACUTE LYMPHOBLASTIC LEUKEMIA: A 12 YEAR EXPERIENCE 94
Recurrent plasmacytomas after allografting in a patient with multiple myeloma. 90
Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation 85
Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting 83
A SALVAGE TREATMENT CONTAINING NOVEL AGENTS CONSOLIDATED BY ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED-INTENSITY CONDITIONING IMPROVES OUTCOME OF MULTIPLE MYELOMA PATIENTS FAILING AUTOLOGOUS TRANSPLANTATION 80
Allografting in relapsed/refractory Hodgkin's lymphoma, a single-centre experience 76
LONG TERM FOLLOW UP OF A COMPARISON OF NONMYELOABLATIVE ALLOGRAFTING WITH AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA 75
Disease and Comorbidity Status Predict Outcome after Nonmyeloablative Allografting for Advanced Haematological Malignancies. 72
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. 70
Induction with New Drugs and Planned Autologous Followed by Non-Myeloablative Allogeneic Transplantation in Newly Diagnosed Myeloma. 63
Total lymphoid irradiation and antithymocyte globulin to reduce graft-versus-host disease after allografting in haematological malignancies: a GITMO experience 62
Efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation at risk of hepatis B virus reactivation 62
Prognostic factors and outcome of reduced-intensity conditioning followed by allogeneic stem cell transplantation in patients with multiple myeloma relapsed after autografting and rescued with new drugs 62
Long-term follow-up of a comparison of non-myeloablative allografting with autografting for newly diagnosed myeloma 61
Role of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma Relapsing After Autograft: a Donor Versus No Donor Analysis 60
Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation 57
Risk of hepatitis B and efficacy of treatment with lamivudine in patients undergoing allo-SCT 52
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 51
Salvage treatment for relapsed/refractory hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents 48
Immune Reconstitution and Thymic Function After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation 44
Totale 10.216
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.714
article - articoli 0
book - libri 0
conference - conferenze 7.329
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.043
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020865 0 0 0 0 0 183 154 119 131 96 103 79
2020/20211.280 113 73 99 77 111 102 121 102 111 98 117 156
2021/20221.022 65 60 60 108 56 38 87 68 49 87 203 141
2022/20231.228 88 124 58 111 91 252 84 85 122 70 71 72
2023/2024765 97 158 49 51 76 116 44 43 12 30 31 58
2024/2025674 18 96 93 122 316 29 0 0 0 0 0 0
Totale 10.216